【正文】 Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and lowdensity lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998。 279。 1955–1961. ? Figure 73. Fruchart JC. Are nuclear factors the ultimate targets of drugs affecting lipid metabolism? Current Atherosclerosis Reports 2022。 2。 353–354. ? Figure 75, 76, 77 and 78. Pennancchio LA, Oliver M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and Mice revealed by parative sequencing. Science 2022。 294。 169–173. ? Figures 82 and 83. Chiti G, Lestavel S, Bocher V, Remaley AT, Neve B, Pineda Torra I, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPARa and PPARg activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2022。 7。 53–58. ? Figure 84 and 85. Chiti G, Baguidi G, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui J, NajibFruchart J, Staels B. CLA1/SRB1 is expressed in atherosclerosis lesion macrophages and regulated by activators of peroxisome proliferatoractivated receptors (PPARs). Circulation 2022。 101。 2411–2417. ? Figure 86. Fruchart JC. PPARa activation and HDL metabolism. Am J Cardiol 2022。 88 supp.。24N–29N. ? Figure 87, 88, 89, 92, 94 and 94. Staels B, Keonig W, Habib A, Merval R, Lebret M, Pineda Torra I,Delerive P, Fadel A, Chiti G, Fruchart JC, Najib J, Maclouf J, Tedgui A . Activation of human aortic smoothmuscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998。 393(6686)。 790–793. ? Figure 90. Delerive Ph, Gervois P, Fruchart JC, Staels B. Induction of IkBa expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferatoractivated receptora activators. J Biol Chem 2022。 275/47。 36703–36707. ? Figures 95. Delerive P, Fruchart JC and Staels B. Peroxisome proliferatoractivated receptors in inflammation control. J Endocrinol 2022。 169。 453–459. ? Figure 96 and 97. Delerive P, MartinNizard F, Chiti G, Trottein G, Fruchart JC, Najib J, Duriez P, Staels B. PPAR activators inhibit thrombininduced endothelin1 production in human vascular endothelial cells by inhibiting the activator protein1 signaling pathway. Circ Red 1999。 85。 394–402. ? Figures 98. Neve BP, Corseaux D, Chiti G Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARa agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2022。103。 207–212. ? Figures 99. Gervois P, VuDac R, Kleeman M, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B. Negative regulation of human fibrinogen gene expression by PPARa agonists via inhibition of C/EBPb. J Biol Chem 2022。 276。 33471–33477. ? Figures 103. Schoonjans K, PeinadoOnsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J. 3hydroxy3methyglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C111 and lipoprotein lipase. FEBS Lett 1999。 452, 160–164. ? Figures 105, 106, 107, 108 and 109. Martin G, Duez H, Blanquart C, Berezowski V, Poilain P, Fruchart JC, NajibFruchart J, Glineur C, Staels, B. Statin induced inhibition of the Rhosignaling pathway activates PPARa and induces HDL apo A1. J Clin Invest 2022 107 1423–1432.